Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?

Di Altobrando, A; Patrizi, A; Bardazzi, F

Di Altobrando, A; Patrizi, A; Bardazzi, F.

Di Altobrando A; Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.
Patrizi A; Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.
Bardazzi F; Department of Experimental, Diagnostic and Specialty Medicine - Division of Dermatology, University of Bologna, Bologna, Italy.

J Eur Acad Dermatol Venereol ; 34(7): e295-e297, 2020 Jul.

Article in English | MEDLINE | ID: covidwho-72081

Subject(s)

Autoimmune Diseases/drug therapy; Blister/drug therapy; Immunosuppressive Agents/therapeutic use; Autoimmune Diseases/complications; Betacoronavirus; Blister/complications; COVID-19; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoimmune Diseases / Blister / Immunosuppressive Agents Topics: Long Covid Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2020 Document Type: Article Affiliation country: Jdv.16491

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google